Health
Sock JohnsonDr Reddy's Dominates with Generic Ozempic Approval!
Dr Reddy's just scored a major victory! They’ve snagged approval to unleash their generic Ozempic, ready to tackle diabetes like a true champion. With 12 million Semaglutide pens primed for launch, they’re flexing a 19% revenue rise despite a minor profit dip. And Canada? They’re coming for you too! Can you feel the electrifying energy of Dr Reddy's? It's time to lay the smackdown!
few days ago | Reuters
Quick rundown
1.Dr Reddy's received approval to sell generic Ozempic.
2.Semaglutide patent expires in March 2026.
3.Dr Reddy's plans to launch Semaglutide in Canada this year.
4.Revenue from India business rose 19% last quarter.
5.Profit decline due to competition in the US market.
